Targets › KAT6
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: the race on KAT6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stemline Therapeutics | MEN2312 KAT6 inhibitor | KAT6 | Phase 1 | Advanced Breast Cancer | Oct 2027 |
| IDEAYA Biosciences | IDE574 KAT6/KAT7 co-inhibitor | KAT6, KAT7 | Phase 1 | Cancer | Dec 2029 |
Cancer (1) Advanced Breast Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.